ReCode Therapeutics is a clinical-stage biotech developing genetic medicines for cystic fibrosis, leveraging its Selective Organ Targeting lipid nanoparticle delivery platform alongside mRNA and gene-editing approaches. Its lead inhaled program, RCT2100, is in a fully enrolled Phase 2a study and received Fast Track designation from the U.S. FDA in February 2026, with data expected in the fourth quarter. The company has entered a research collaboration with an undisclosed gene-editing company to co-develop therapies that correct CFTR mutations, combining ReCode's delivery technology with the partner's editing platform. The collaboration and funding from the Cystic Fibrosis Foundation are intended to advance one or more candidates toward clinical development and commercialization. Recent leadership changes include Heather Clark being named CEO and former CEO Shehnaaz Suliman becoming executive chair of the board. Clark joined ReCode in 2022 and has extensive rare-disease and cystic fibrosis drug development experience, including more than two decades at Vertex Pharmaceuticals.

Total raised

$584M

Funding rounds

8

Latest round

Equity

Latest activity

Sep 2025